Daily Bulletin

Men's Weekly

.

First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

SYDNEY, Feb. 25, 2022 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), a clinical-stage radiopharmaceutical company developing next-generation products to address the growing needs in oncology, is pleased to announce that it has successfully treated its first participant in cohort 2 of the 64Cu/67Cu SARTATE™ neuroblastoma...

Read more: First patient treated in cohort 2 SARTATE™ neuroblastoma therapy trial

Business News

Digital Marketing Agency in Sydney: Empowering Businesses with Smart Online Growth Strategies

Sydney’s business scene is fast-paced, diverse, and incredibly competitive. In such a dynamic environment, having a strong online presence is no longer optional — it’s essential. A digital marketing...

Daily Bulletin - avatar Daily Bulletin

Why Your Business Might Already Be a Cybercrime Target Without Knowing It

Cybercrime isn’t just something that happens to banks or large technology companies. It can happen to any business, even those that seem too small to matter. When a hacker sees an easy target, they ta...

Daily Bulletin - avatar Daily Bulletin

Car Rental as a Practical and Flexible Solution for Travel or Work

The contemporary, hectic way of life is one of ease and adaptability while commuting and working. Regardless of whether one moves around by road, commuting between towns for conferences, or taking a f...

Daily Bulletin - avatar Daily Bulletin

Speed Dating For Business